Search - tctmd.com

Displaying 81 - 98 of 98

Sort: Relevancy | Date

Presentation ESC 2013

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Presenter: 32040|Roxana Mehran

September 01, 2013

News Conference News ESC 2013

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

Yael L. Maxwell

September 01, 2013

News Daily News

HORIZONS-AMI: Bivalirudin, Taxus Improve Outcomes in LAD PCI Patients

Leah Lawrence

July 11, 2013

Presentation

Decision Dilemmas in Adjunctive Pharmacology Choices in PCI Patients

Presenter: Roxana Mehran

April 15, 2013

News Conference News ACC 2013

Rosuvastatin Helps Stave Off Contrast Nephropathy in NSTE-ACS Patients

L.A. McKeown

March 09, 2013

News Conference News ACC 2013

Cangrelor Consistently Comes Out Ahead of Clopidogrel in All PCI Patients

Yael L. Maxwell

March 09, 2013

Presentation TCT 2013

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Presenter: Andreas Baumbach, Harold Dauerman, Bernardo Cortese, Martial Hamon, Jayne Prats, Efthymios Deliargyris, Roxana Mehran, Gregg Stone

January 31, 2013

News Daily News

Una Dosis Alta de Aspirina tras una PCI Primaria aumenta las Hemorragias No observandose Beneficio Isquémico alguno

L.A. McKeown

December 19, 2012

News Daily News

High-Dose Aspirin After Primary PCI Increases Bleeding with No Ischemic Benefit

L.A. McKeown

December 19, 2012

Presentation TCT 2012

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Roxana Mehran

October 25, 2012

Presentation TCT 2012

Factor IXa Inhibition (Aptamer) Update

Presenter: Roxana Mehran

October 24, 2012

Presentation TCT 2012

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

Presenter: Roxana Mehran

October 22, 2012

News Daily News

La Bivalirudina Reduce las Hemorragias en Pacientes NSTEMI sometidos a PCI

Jason Kahn

October 19, 2012

News Daily News

Bivalirudin Lowers Bleeding in NSTEMI Patients Undergoing PCI

Jason Kahn

October 19, 2012

Presentation Fellows 2012

Oral Antiplatelet Agents in PCI and ACS

Presenter: Roxana Mehran

April 22, 2012

Presentation TCT 2012

Bivalirudin Use During Percutaneous Coronary Intervention Improves Clinical and Economic Outcomes in Diabetic Women

Presenter: Erin M. Galbraith, Roxana Mehran, Chandan Devireddy, Henry A. Liberman, Steven V. Manoukian, Michele D. Voeltz

January 03, 2012

News Daily News

HORIZONS-AMI: CKD Patients Fare Poorly Regardless of Stent Type, Antithrombotic Regimen

Leah Lawrence

September 29, 2011

News Daily News

BARC: New Bleeding Definitions Aim to Standardize Trial Endpoints

L.A. McKeown

June 17, 2011

Advertisement

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

HORIZONS-AMI: Bivalirudin, Taxus Improve Outcomes in LAD PCI Patients

Decision Dilemmas in Adjunctive Pharmacology Choices in PCI Patients

Rosuvastatin Helps Stave Off Contrast Nephropathy in NSTE-ACS Patients

Cangrelor Consistently Comes Out Ahead of Clopidogrel in All PCI Patients

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Una Dosis Alta de Aspirina tras una PCI Primaria aumenta las Hemorragias No observandose Beneficio Isquémico alguno

High-Dose Aspirin After Primary PCI Increases Bleeding with No Ischemic Benefit

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

Factor IXa Inhibition (Aptamer) Update

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

La Bivalirudina Reduce las Hemorragias en Pacientes NSTEMI sometidos a PCI

Bivalirudin Lowers Bleeding in NSTEMI Patients Undergoing PCI

Oral Antiplatelet Agents in PCI and ACS

Bivalirudin Use During Percutaneous Coronary Intervention Improves Clinical and Economic Outcomes in Diabetic Women

HORIZONS-AMI: CKD Patients Fare Poorly Regardless of Stent Type, Antithrombotic Regimen

BARC: New Bleeding Definitions Aim to Standardize Trial Endpoints

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content